ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
대장암 치료제 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에 CAGR은 5.6%를 나타낼 것으로 예측되고 270억 1,000만 달러로 성장할 전망입니다. 예측 기간 동안의 성장은 맞춤형 치료 증가, 환자 중심 치료 모델, 표적 치료 확대, 복합 치료 도입, 규제 가속화에 기인할 수 있습니다. 예측 기간의 주요 동향에는 면역요법 발전, 정밀의학 진화, 병용요법, 바이오마커 연구 및 활용, 임상시험 혁신 등이 포함됩니다.
향후 5년간 5.6% 성장 전망은 이 시장에 대한 이전 추정치 대비 0.3% 소폭 하향 조정된 수치입니다. 이 하향 조정은 주로 미국과 타국 간 관세 영향에 기인합니다. 무역 갈등은 프랑스와 영국에서 개발된 혈관내피성장인자 억제제 대장암 치료제의 가격 상승을 유발하여 미국 종양학 센터의 운영을 저해할 수 있으며, 이는 전이성 치료 옵션의 제한과 위장관 종양학 치료 비용 증가로 이어질 수 있습니다. 또한 상호 관세 부과와 무역 갈등 및 제한 강화로 인한 전 세계 경제 및 무역에 대한 부정적 영향으로 그 영향이 더욱 광범위하게 될 것입니다.
맞춤형 의약품에 대한 수요 증가는 향후 대장암 의약품 시장을 촉진할 것으로 예상됩니다. 정밀의학으로도 알려진 맞춤형 의학은 환자의 유전자, 환경, 생활 방식의 개인차를 고려한 의료 치료 및 건강 관리 접근법입니다. 이 접근법은 대장암(CRC) 치료에 혁신을 가져와 환자에게 보다 개별화되고 효과적인 치료를 제공하고 있습니다. 연구 및 의약품 개발이 특정 유전적·분자적 프로파일에 점점 더 맞춤화됨에 따라, 이는 대장암 의약품 시장의 성장을 지속적으로 촉진할 것으로 보입니다. 예를 들어, 2024년 2월 미국 비영리 단체인 맞춤형의학연합(Personalized Medicine Coalition)은 FDA가 2023년 희귀질환 환자를 위한 16개의 새로운 맞춤형 의약품 치료법을 승인했다고 보고했으며, 이는 2022년 승인된 6개 대비 상당한 증가입니다. 따라서 맞춤형 의약품에 대한 수요 증가는 대장암 치료제 시장 확장을 촉진하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 대장암 치료제 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 대장암 치료제 시장 : 성장률 분석
세계의 대장암 치료제 시장 실적 : 규모와 성장(2019-2024년)
세계의 대장암 치료제 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 대장암 치료제 : 총 잠재시장 규모(TAM)
제6장 시장 세분화
세계의 대장암 치료제 시장 : 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
혈관 내피 성장 인자(VEGF) 억제제
상피 성장 인자 수용체(EGFR) 억제제
프로그램 세포 사멸 단백질 1 또는 PD1 리간드 1(PD1 또는 PDL1) 억제제
BRAF 또는 MEK 억제제
티로신 키나아제(TKI) 억제제
면역조절제
세계의 대장암 치료제 시장 : 클래스별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
면역요법
화학요법
기타 클래스
세계의 대장암 치료제 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원 약국
소매 약국
기타 유통 채널
세계의 대장암 치료제 시장, 혈관 내피 성장 인자(VEGF) 억제제 유형별 세분화 : 분석과 예측
베바시주맙
람실마맙
기타 VEGF 억제제
세계의 대장암 치료제 시장, 상피 성장 인자 수용체(EGFR) 억제제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세툭시맙
파니툼맙
기타 EGFR 억제제
세계의 대장암 치료제 시장, 프로그램 세포 사멸 단백질 1(PD1 또는 PDL1) 억제제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
펜브롤리주맙
니볼루맙
기타 PD1 또는 PDL1 억제제
세계의 대장암 치료제 시장, BRAF 또는 MEK 억제제 유형별 세분화 : 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 대장암 치료제 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 대장암 치료제 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
대장암 치료제 시장 : 경쟁 구도
대장암 치료제 시장 : 기업 프로파일
Pfizer Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck & Co. Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
AbbVie Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Bayer AG : 개요, 제품 및 서비스, 전략 및 재무 분석
Novartis AG : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Sanofi SA
Bristol-Myers Squibb Company
AstraZeneca plc
Takeda Pharmaceutical Company Limited
F. Hoffmann-La Roche Ltd.
Eli Lilly and Company
Amgen Inc.
Astellas Pharma Inc.
Servier Laboratories
Eisai Co. Ltd.
Sumitomo Dainippon Pharma Co. Ltd.
Ipsen SA
Taiho Pharmaceutical Co. Ltd.
Kyowa Kirin Co. Ltd.
Taiho Oncology Inc.
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
대장암 치료제 시장(2029년) : 새로운 기회를 제공하는 국가
대장암 치료제 시장(2029년) : 새로운 기회를 제공하는 부문
대장암 치료제 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
HBR
영문 목차
영문목차
Colorectal cancer (CRC) or bowel cancer is a form of cancer that affects the large intestine and the rectum. Depending on their origin, these cancers are referred to as either colon tumors or rectal cancer.
The main types of drugs used for colorectal cancer treatment include vascular endothelial growth factor (VEGF) inhibitors, epidermal growth factor receptor (EGFR) inhibitors, programmed cell death protein 1/PD1 ligand 1 (PD1/PDL1) inhibitors, BRAF or MEK inhibitors, tyrosine kinase (TKI) inhibitors, and immunomodulators. Vascular endothelial growth factor (VEGF) inhibitors are drugs that block VEGF and VEGFR activity. The different classes of drugs include immunotherapy, chemotherapy, and others, and these medications are typically dispensed through hospital pharmacies, retail pharmacies, and other distribution channels.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The colorectal cancer drugs market research report is one of a series of new reports from The Business Research Company that provides colorectal cancer drugs market statistics, including colorectal cancer drugs industry global market size, regional shares, competitors with a colorectal cancer drugs market share, detailed colorectal cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the colorectal cancer drugs industry. This colorectal cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The colorectal cancer drugs market size has grown steadily in recent years. It will grow from $20.72 billion in 2024 to $21.72 billion in 2025 at a compound annual growth rate (CAGR) of 4.8%. The growth in the historic period can be attributed to integration of multimodal approaches, introduction of chemotherapy, advancements in surgical techniques, emergence of targeted therapies, clinical trials and research.
The colorectal cancer drugs market size is expected to see strong growth in the next few years. It will grow to $27.01 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to rise in personalized treatment, patient-centric care models, expansion of targeted therapies, adoption of combination therapies, regulatory acceleration. Major trends in the forecast period include immunotherapy advancements, precision medicine evolution, combination therapies, biomarker research and use, clinical trials innovation.
The forecast of 5.6% growth over the next five years reflects a modest reduction of 0.3% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology centers by inflating prices of vascular endothelial growth factor inhibitor colorectal cancer therapies developed in France and the UK, resulting in limited metastatic treatment options and higher GI oncology care costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising demand for personalized medicines is expected to drive the growth of the colorectal cancer drugs market in the future. Personalized medicine, also known as precision medicine, is an approach to medical treatment and healthcare that considers individual differences in patients' genes, environments, and lifestyles. This approach is revolutionizing the treatment of colorectal cancer (CRC), providing more individualized and effective care for patients. As research and drug development become increasingly tailored to specific genetic and molecular profiles, it is likely to continue propelling the growth of the CRC drug market. For example, in February 2024, the Personalized Medicine Coalition, a US-based non-profit organization, reported that the FDA approved 16 new personalized therapies for patients with rare diseases in 2023, a significant rise from the six approved in 2022. Therefore, the growing demand for personalized medicine is driving the expansion of the colorectal cancer drugs market.
The colorectal cancer drugs market is also expected to witness growth due to the escalating number of clinical trials. Clinical trials, involving human volunteers, evaluate the safety and efficacy of various medical treatments, including drugs designed for colorectal cancer treatment. These trials play a crucial role in identifying novel therapies that can enhance patient outcomes, potentially introducing new drugs to the market. The substantial increase in the number of clinical trials, with over 452,000 registered studies and more than 64,000 actively seeking participants, as reported by Xtalks in May 2023, indicates a significant rise compared to early 2021. This surge in clinical trials is contributing to the growth of the colorectal cancer drugs market.
Major companies in the colorectal cancer drugs market are focused on gaining FDA approvals for new drugs to enhance profitability. An example is LONSURF (trifluridine/tipiracil), an oral prescription medication approved by the FDA for treating specific cancers such as colon, rectal, and stomach cancer that has metastasized. Taiho Pharmaceutical Co. Ltd. announced FDA approval for LONSURF in combination with bevacizumab for treating metastatic colorectal cancer in August 2023. The combination significantly increased overall and progression-free survival compared to LONSURF alone.
In October 2023, the Bristol-Myers Squibb Company acquired Mirati Therapeutics Inc for $5.8 billion. This strategic move aimed to add KRAZATI, a prominent lung cancer drug, to Bristol Myers Squibb's commercial portfolio, enhancing and diversifying its oncology offerings. The acquisition aligns with Bristol-Myers Squibb's mission to uncover scientific advancements that promise a life free from cancer. Mirati Therapeutics Inc., a US-based biotech company, contributes valuable therapies to Bristol-Myers Squibb's efforts in the field of oncology.
Major companies operating in the colorectal cancer drugs market include Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Servier Laboratories, Eisai Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Ipsen SA, Taiho Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Taiho Oncology Inc., Ono Pharmaceutical Co. Ltd., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Mundipharma International Limited, Teva Pharmaceutical Industries Ltd., Gilead Sciences Inc., Johnson & Johnson Services Inc., Spectrum Pharmaceuticals Inc., Exelixis Inc., Seattle Genetics Inc., Incyte Corporation, Clovis Oncology Inc., Karyopharm Therapeutics Inc.
North America was the largest region in the colorectal cancer drugs market in 2024. The Middle East is expected to be the fastest-growing region in the global colorectal cancer drugs market share during the forecast period. The regions covered in the colorectal cancer drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the colorectal cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The colorectal cancer drugs market consists of sales of avastin, bevacizumab, and camptosar. Values in the colorectal cancer drugs market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Colorectal Cancer Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on colorectal cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for colorectal cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The colorectal cancer drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Type: Vascular Endothelial Growth Factor (VEGF) Inhibitors; Epidermal Growth Factor Receptor (EGFR) Inhibitors; Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors; BRAF Or MEK Inhibitors; Tyrosine Kinase (TKI) Inhibitors; Immunomodulators
2) By Class: Immunotherapy; Chemotherapy; Other Classes
3) By Distribution Channels: Hospitals Pharmacies; Retail Pharmacies; Other Distribution Channels
Subsegments:
1) By Vascular Endothelial Growth Factor (VEGF) Inhibitors: Bevacizumab; Ramucirumab; Other VEGF Inhibitors
2) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Cetuximab; Panitumumab; Other EGFR Inhibitors
3) By Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors: Pembrolizumab; Nivolumab; Other PD1 Or PDL1 Inhibitors
4) By BRAF Or MEK Inhibitors: Vemurafenib; Encorafenib; Trametinib; Other BRAF Or MEK Inhibitors
5) By Tyrosine Kinase (TKI) Inhibitors: Regorafenib; Sorafenib; Other TKI Inhibitors
6) By Immunomodulators: Checkpoint Inhibitors; Other Immunomodulating Agents
Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi SA; Bristol-Myers Squibb Company; AstraZeneca plc; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd.; Eli Lilly and Company; Amgen Inc.; Astellas Pharma Inc.; Servier Laboratories; Eisai Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Ipsen SA; Taiho Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.; Taiho Oncology Inc.; Ono Pharmaceutical Co. Ltd.; Daiichi Sankyo Company Limited; Otsuka Pharmaceutical Co. Ltd.; Mundipharma International Limited; Teva Pharmaceutical Industries Ltd.; Gilead Sciences Inc.; Johnson & Johnson Services Inc.; Spectrum Pharmaceuticals Inc.; Exelixis Inc.; Seattle Genetics Inc.; Incyte Corporation; Clovis Oncology Inc.; Karyopharm Therapeutics Inc.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Colorectal Cancer Drugs Market Characteristics
3. Colorectal Cancer Drugs Market Trends And Strategies
4. Colorectal Cancer Drugs Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Colorectal Cancer Drugs Growth Analysis And Strategic Analysis Framework
5.1. Global Colorectal Cancer Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Colorectal Cancer Drugs Market Growth Rate Analysis
5.4. Global Colorectal Cancer Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Colorectal Cancer Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Colorectal Cancer Drugs Total Addressable Market (TAM)
6. Colorectal Cancer Drugs Market Segmentation
6.1. Global Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors
BRAF Or MEK Inhibitors
Tyrosine Kinase (TKI) Inhibitors
Immunomodulators
6.2. Global Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Immunotherapy
Chemotherapy
Other Classes
6.3. Global Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals Pharmacies
Retail Pharmacies
Other Distribution Channels
6.4. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Vascular Endothelial Growth Factor (VEGF) Inhibitorsm, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Bevacizumab
Ramucirumab
Other VEGF Inhibitors
6.5. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Epidermal Growth Factor Receptor (EGFR) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Cetuximab
Panitumumab
Other EGFR Inhibitors
6.6. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Programmed Cell Death Protein 1 Or PD1 Ligand 1 (PD1 Or PDL1) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pembrolizumab
Nivolumab
Other PD1 Or PDL1 Inhibitors
6.7. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of BRAF Or MEK Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Vemurafenib
Encorafenib
Trametinib
6.8. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Tyrosine Kinase (TKI) Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Regorafenib
Sorafenib
Other TKI Inhibitors
6.9. Global Colorectal Cancer Drugs Market, Sub-Segmentation Of Immunomodulators, By type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Checkpoint Inhibitors
Other Immunomodulating Agents
7. Colorectal Cancer Drugs Market Regional And Country Analysis
7.1. Global Colorectal Cancer Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Colorectal Cancer Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Colorectal Cancer Drugs Market
8.1. Asia-Pacific Colorectal Cancer Drugs Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Colorectal Cancer Drugs Market
9.1. China Colorectal Cancer Drugs Market Overview
9.2. China Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Colorectal Cancer Drugs Market
10.1. India Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Colorectal Cancer Drugs Market
11.1. Japan Colorectal Cancer Drugs Market Overview
11.2. Japan Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Colorectal Cancer Drugs Market
12.1. Australia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Colorectal Cancer Drugs Market
13.1. Indonesia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Colorectal Cancer Drugs Market
14.1. South Korea Colorectal Cancer Drugs Market Overview
14.2. South Korea Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Colorectal Cancer Drugs Market
15.1. Western Europe Colorectal Cancer Drugs Market Overview
15.2. Western Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Colorectal Cancer Drugs Market
16.1. UK Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Colorectal Cancer Drugs Market
17.1. Germany Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Colorectal Cancer Drugs Market
18.1. France Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Colorectal Cancer Drugs Market
19.1. Italy Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Colorectal Cancer Drugs Market
20.1. Spain Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Colorectal Cancer Drugs Market
21.1. Eastern Europe Colorectal Cancer Drugs Market Overview
21.2. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Colorectal Cancer Drugs Market
22.1. Russia Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Colorectal Cancer Drugs Market
23.1. North America Colorectal Cancer Drugs Market Overview
23.2. North America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Colorectal Cancer Drugs Market
24.1. USA Colorectal Cancer Drugs Market Overview
24.2. USA Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Colorectal Cancer Drugs Market
25.1. Canada Colorectal Cancer Drugs Market Overview
25.2. Canada Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Colorectal Cancer Drugs Market
26.1. South America Colorectal Cancer Drugs Market Overview
26.2. South America Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Colorectal Cancer Drugs Market
27.1. Brazil Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Colorectal Cancer Drugs Market
28.1. Middle East Colorectal Cancer Drugs Market Overview
28.2. Middle East Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Colorectal Cancer Drugs Market
29.1. Africa Colorectal Cancer Drugs Market Overview
29.2. Africa Colorectal Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Colorectal Cancer Drugs Market, Segmentation By Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Colorectal Cancer Drugs Market, Segmentation By Distribution Channels, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Colorectal Cancer Drugs Market Competitive Landscape And Company Profiles
30.1. Colorectal Cancer Drugs Market Competitive Landscape
30.2. Colorectal Cancer Drugs Market Company Profiles
30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
30.2.4. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
31. Colorectal Cancer Drugs Market Other Major And Innovative Companies
31.1. Sanofi SA
31.2. Bristol-Myers Squibb Company
31.3. AstraZeneca plc
31.4. Takeda Pharmaceutical Company Limited
31.5. F. Hoffmann-La Roche Ltd.
31.6. Eli Lilly and Company
31.7. Amgen Inc.
31.8. Astellas Pharma Inc.
31.9. Servier Laboratories
31.10. Eisai Co. Ltd.
31.11. Sumitomo Dainippon Pharma Co. Ltd.
31.12. Ipsen SA
31.13. Taiho Pharmaceutical Co. Ltd.
31.14. Kyowa Kirin Co. Ltd.
31.15. Taiho Oncology Inc.
32. Global Colorectal Cancer Drugs Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Colorectal Cancer Drugs Market
34. Recent Developments In The Colorectal Cancer Drugs Market
35. Colorectal Cancer Drugs Market High Potential Countries, Segments and Strategies
35.1 Colorectal Cancer Drugs Market In 2029 - Countries Offering Most New Opportunities
35.2 Colorectal Cancer Drugs Market In 2029 - Segments Offering Most New Opportunities
35.3 Colorectal Cancer Drugs Market In 2029 - Growth Strategies
